Ariad Gets $10M From Merck
Luke Timmerman3/2/09
Cambridge, MA-based Ariad Pharmaceuticals said today that it expects to receive a $10 million milestone payment from its partner, Merck, in connection with the start of a mid-stage clinical trial of Ariad’s experimental drug for lung cancer. The company (NASDAQ: ARIA) used up $48 million of its cash reserves during 2008, and ended the year with $39.1 million left in the bank.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
